*NEWS: ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration
ChromaDex, with HQ in Irvine, has received approval from the Australian Therapeutic Goods Administration for its patented nicotinamide riboside chloride (NR) for use in listed complementary medicines. The listing indicates that ChromaDex has market exclusivity of NR through December 2021, according to a December 2 press release issued by the company.
With this approval, ChromaDex will be listing their final product as a complementary medicine on the Australian Register of Therapeutic Goods.
“This is an important milestone as we expand our presence in the Asia-Pacific region,” ChromaDex CEO Rob Fried said in the release.
Cells can use NR to create nicotinamide adenine dinucleotide (NAD), an essential molecule found in every living cell. NAD plays an essential role in cellular energy production and supporting cellular repair. Decreased NAD levels are associated with many age-related declines in overall health.
ChromaDex’s product, Niagen, has twice been successfully reviewed under FDA new dietary ingredient notification requirements and has also been successfully notified to the FDA as generally recognized as safe.
In August, the European Food Safety Authority issued a positive opinion on NR as a novel food ingredient for use in a food supplement; in November, the European Commission voted in favor of listing nicotinamide riboside chloride as a novel food.
To date, ChromaDex has invested millions of dollars in safety and human clinical trials on its patent-protected NR and has entered research agreements with more than 170 leading research institutions, including Dartmouth and the National Institutes of Health.